1. Home
  2. CFFN vs URGN Comparison

CFFN vs URGN Comparison

Compare CFFN & URGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Capitol Federal Financial Inc.

CFFN

Capitol Federal Financial Inc.

N/A

Current Price

$6.93

Market Cap

977.3M

Sector

Finance

ML Signal

N/A

Logo UroGen Pharma Ltd.

URGN

UroGen Pharma Ltd.

N/A

Current Price

$18.78

Market Cap

922.1M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CFFN
URGN
Founded
1893
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Savings Institutions
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
977.3M
922.1M
IPO Year
2010
2016

Fundamental Metrics

Financial Performance
Metric
CFFN
URGN
Price
$6.93
$18.78
Analyst Decision
Hold
Strong Buy
Analyst Count
2
7
Target Price
$7.25
$29.29
AVG Volume (30 Days)
783.0K
816.7K
Earning Date
01-01-0001
06-10-2026
Dividend Yield
4.91%
N/A
EPS Growth
79.31
N/A
EPS
0.16
N/A
Revenue
$16,300,000.00
$1,128,000.00
Revenue This Year
$20.16
$119.37
Revenue Next Year
$6.62
$64.79
P/E Ratio
$43.31
N/A
Revenue Growth
6.54
N/A
52 Week Low
$4.90
$3.42
52 Week High
$7.84
$30.00

Technical Indicators

Market Signals
Indicator
CFFN
URGN
Relative Strength Index (RSI) 41.30 42.20
Support Level $6.08 $18.55
Resistance Level $7.31 $20.44
Average True Range (ATR) 0.18 1.40
MACD -0.05 -0.15
Stochastic Oscillator 27.59 23.84

Price Performance

Historical Comparison
CFFN
URGN

About CFFN Capitol Federal Financial Inc.

Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It mainly serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.

About URGN UroGen Pharma Ltd.

UroGen Pharma Ltd is a clinical-stage biotechnology firm specializing in solutions for urothelial and specialty cancers. The company has developed RTGel reverse-thermal hydrogel, a proprietary technology enhancing the therapeutic profiles of existing drugs by enabling sustained release. Their flagship product, Jelmyto (mitomycin) for pyelocalyceal solution, along with investigational candidate UGN-102 (mitomycin) for intravesical solution, targets non-surgical tumor ablation in forms of non-muscle invasive urothelial cancer. Additionally, their immuno-uro-oncology pipeline includes UGN-301 (zalifrelimab), an anti-CTLA-4 antibody, intended for both monotherapy and combination therapy. Revenue is generated from product sales.

Share on Social Networks: